Q-omics provides the consensus-scored ZDHHC20P3 profile across patient tissues and cancer cell-line models. ZDHHC20P3 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ZDHHC20P3 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, ZDHHC20P3 RNA expression shows 7,110 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight COAD, THCA, and PCPG as cancer lineages where ZDHHC20P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC20P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC20P3 survival associations across molecular data types. ZDHHC20P3 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC20P3 RNA expression–survival associations across cancer types. High ZDHHC20P3 expression shows unfavorable associations in COAD, KICH, ACC, UCS, KIRC and UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ZDHHC20P3 RNA expression.
This table summarizes ZDHHC20P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC20P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC20P3 shows lower tumor expression in THCA. The THCA box plot shows higher ZDHHC20P3 RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p = .039).
This table shows molecular features associated with ZDHHC20P3 in patient tissues and cancer cell lines. In patient samples, ZDHHC20P3 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
